CYRX · CryoPort, Inc. · Stock research

Current Thesis

Cryoport is the picks-and-shovels cold-chain layer for cell & gene therapy (CGT): cryogenic logistics, storage, and packaging that taxes the entire CGT pipeline rather than betting on which therapy wins. The 2026 re-rate ran on three legs FDA loosening CGT manufacturing requirements (Jan 2026), a biotech-funding recovery refilling the trial pipeline, and accelerating commercial CGT revenue (+26% YoY at the 2026-05-04 Q1 print). That move has now matured. Craig-Hallum's push to a street-high $20 (2026-06-03) marked the top; the stock printed a 52-week high of $16.73 and has since faded ~9% to churn a tightening $15–16 range, last around $15.26 (2026-07-09/10). The sell-side has both converged and cooled: the 10-analyst consensus target has drifted from $15.61 to $15.11 (2026-07-08), now sitting just below spot, and the rating has slipped from unanimous Buy to Moderate Buy with two holds added. Jefferies stamped a $13.50 target on 2026-06-08 below the current price. The C-suite distributed into the pop (CFO sold 61% of his stake at a weighted $16.27 on 2026-06-04). No company-specific binary lands until the confirmed Q2 print on 2026-08-11, so the next four weeks trade on biotech risk appetite alone. Entry at $15+ into a below-spot consensus and an approaching earnings blackout is the late-entry chase; the better-defined setup is a retest of the $13–14 breakout shelf paired with Q2 commercial-CGT re-acceleration.

Bullish and bearish views on CryoPort, Inc.

The model's bull view on CryoPort, Inc. (CYRX), in brief: Commercial CGT revenue +26% YoY to $9.1M (Q1 2026, 2026-05-04) the high-margin recurring leg is accelerating, distinct from the lumpier clinical leg. The bear view: The re-rate is spent and the sell-side is rolling over: consensus target drifted from $15.61 (June) to $15.11 (2026-07-08), now below the ~$15.26 spot, and the rating fell from unanimous Buy to Moderate Buy as two firms moved to hold. Both cases follow in full.

Bull Case

• Commercial CGT revenue +26% YoY to $9.1M (Q1 2026, 2026-05-04) the high-margin recurring leg is accelerating, distinct from the lumpier clinical leg.
• Q1 revenue $47.8M, +16% YoY, beat the ~$45M consensus; Life Sciences Services +18% YoY to $26.9M (2026-05-04).
• FY2026 revenue guide of $190–194M (8-K, 2026-05-04); a third-party DCF model lifted its revenue-growth assumption from -3.78% to +9.61% on the improved visibility (2026-05-03).
• Path to profitability narrowing: Q1 adjusted EBITDA -$0.6M, gross margin 45.8%; management guides positive adjusted EBITDA in 2H 2026 on organic growth plus completed facility investments (Q1 call, 2026-05-04).
• New product cycle: the MVE Fusion 800 self-sustaining cryogenic freezer (removes the continuous liquid-nitrogen requirement) won the ISBER Outstanding New Product Award TAM extension into hospitals, clinics, biorepositories, and blood/tissue banks.
• Regulatory and reimbursement tailwind: FDA CGT manufacturing flexibility (Jan 2026) plus the CMS Cell & Gene Therapy Access Model widen the trial-to-commercial funnel, pulling more cold-chain volume downstream.
• Coverage still skews positive: 8 of 10 analysts Buy; Craig-Hallum street-high $20 (2026-06-03), BTIG $17 (2026-05-05). The name also crossed back above its ~$11.07 200-day moving average (2026-07-11), keeping the long-term trend intact.

Bear Case

• The re-rate is spent and the sell-side is rolling over: consensus target drifted from $15.61 (June) to $15.11 (2026-07-08), now below the ~$15.26 spot, and the rating fell from unanimous Buy to Moderate Buy as two firms moved to hold. Jefferies set $13.50 (2026-06-08), a target under current price.
• The Craig-Hallum $20 pop that produced the $16.73 high has faded ~9% within weeks the late-entry signature of a single-note sentiment move with no fundamental catalyst behind it.
• right at the high; Chief Digital/Tech Officer Zecchini and Director Mandalam also sold in early June.
• Still unprofitable: Q1 operating loss widened to $9.6M (from $7.2M YoY); EPS -$0.23 missed by a penny (2026-05-04). Positive adjusted EBITDA remains a 2H-2026 guide, not a print.
• Valuation is full on the right metric: ~$760M market cap and P/S ~4.5x on ~$190M revenue. The low reported PE on data feeds is an artifact the company is operating-loss-making, so use P/S, not PE.
• Demand is downstream of CGT-developer funding. A biotech risk-off tape (XBI rollover, rates higher-for-longer) removes the tailwind faster than any company action can offset it.
• A four-week catalyst vacuum into the 2026-08-11 print, with price stuck in a tightening $15–16 band and no fresh upside driver, is a low-reward holding zone.

Setup & Price Structure

• Spot ~$15.26 (2026-07-09/10), roughly 9% off the $16.73 52-week high set in June; 52-week range $6.69–$16.73. The tape has coiled into a $15–16 range for about four weeks with declining momentum.
• Consensus average target $15.11 now sits just below spot; only Craig-Hallum $20 and BTIG $17 print meaningfully above, while Jefferies $13.50 sits below. Price is already at the sell-side center of gravity the "3-6 weeks ahead of sell-side" edge that defined this name through May is gone.
• Support architecture: the $13–14 breakout base / 20-week EMA zone is the first real shelf; the 200-day MA near $11.07 is far below.
• The higher-probability long is a pullback to $13–14 that holds as a higher low, confirmed by Q2 commercial-CGT re-acceleration not a chase at the top of the range into an earnings blackout.
• Picks-and-shovels behaviour: standard sizing, no retail-squeeze dynamics. This is downstream of biotech funding sentiment, so XBI is the macro tell to watch.

Catalyst Calendar (next 30 days)

• 2026-08-11 (confirmed) Q2 2026 earnings. EARNINGS BLACKOUT: avoid any fresh entry within 3 trading days. Watch commercial CGT revenue growth (was +26% YoY), FY2026 guide vs the $190–194M range, and progress toward the guided 2H-2026 positive adjusted EBITDA.
• Unscheduled / ongoing MVE Fusion 800 commercial-order datapoints (early-ramp orders would be an off-calendar positive); XBI and biotech-funding headlines as the macro driver; any further analyst revisions widening or closing the Jefferies $13.50 vs Craig-Hallum $20 spread.
• No CYRX-specific FDA/PDUFA binary as the logistics layer, it is exposed to CGT approvals in aggregate, not to a single dated decision.

What Would Change Our Mind

• Bullish re-acceleration: a weekly close reclaiming $16.73 on volume a breakout from the four-week range alongside Q2 commercial CGT growth holding above +26% YoY and the 2H-2026 adjusted-EBITDA-positive guide reaffirmed. That would flip the read back to ACCELERATING and justify pressing strength rather than waiting for the $13–14 retest.
• Thesis break: a weekly close below $13 loses the breakout base and the 20-week EMA zone, turning the structure lower; a secondary confirmation would be a FY2026 revenue guide cut below $190M at the Aug 11 print, or commercial CGT revenue growth decelerating below +15% YoY (from +26%).

Correlation Notes

• The dominant macro driver is biotech-funding sentiment XBI direction and CGT-developer trial capital. Demand is downstream of that funnel, so risk-off in small-cap biotech hits CYRX before any company-specific news does.
• Rate-sensitive in the small-cap-biotech mold: a higher-for-longer regime pressures the trial-to-commercial funnel that feeds cold-chain volume.
• Idiosyncratic versus single-therapy CGT names (CRSP, NTLA, BEAM) CYRX taxes pipeline breadth rather than betting on one approval, so it tracks CGT volume and trial count more than any individual readout.
• Partial read-through to broader cold-chain/logistics peers, but the cryogenic-CGT niche is narrow enough that generic freight comps are a weak proxy.